- Home
- BBIO vs DCI Comparison
BBIO vs DCI Comparison
Compare BBIO & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- DCI
- Stock Information
- Founded
- BBIO 2015
- DCI 1915
- Country
- BBIO United States
- DCI United States
- Employees
- BBIO N/A
- DCI N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- DCI Pollution Control Equipment
- Sector
- BBIO Health Care
- DCI Industrials
- Exchange
- BBIO Nasdaq
- DCI Nasdaq
- Market Cap
- BBIO 10.4B
- DCI 9.6B
- IPO Year
- BBIO 2019
- DCI 1987
- Fundamental
- Price
- BBIO $66.62
- DCI $83.58
- Analyst Decision
- BBIO Strong Buy
- DCI Hold
- Analyst Count
- BBIO 16
- DCI 3
- Target Price
- BBIO $65.88
- DCI $80.33
- AVG Volume (30 Days)
- BBIO 2.2M
- DCI 439.7K
- Earning Date
- BBIO 10-29-2025
- DCI 12-02-2025
- Dividend Yield
- BBIO N/A
- DCI 1.45%
- EPS Growth
- BBIO N/A
- DCI N/A
- EPS
- BBIO N/A
- DCI 3.05
- Revenue
- BBIO $235,812,000.00
- DCI $3,690,900,000.00
- Revenue This Year
- BBIO $115.12
- DCI $4.36
- Revenue Next Year
- BBIO $65.29
- DCI $4.52
- P/E Ratio
- BBIO N/A
- DCI $27.14
- Revenue Growth
- BBIO 7.62
- DCI 2.92
- 52 Week Low
- BBIO $21.72
- DCI $57.45
- 52 Week High
- BBIO $65.00
- DCI $84.56
- Technical
- Relative Strength Index (RSI)
- BBIO 77.10
- DCI 53.39
- Support Level
- BBIO $52.75
- DCI $82.51
- Resistance Level
- BBIO $65.00
- DCI $84.56
- Average True Range (ATR)
- BBIO 2.34
- DCI 1.39
- MACD
- BBIO 1.00
- DCI -0.11
- Stochastic Oscillator
- BBIO 80.66
- DCI 60.43
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.